Promoties & Publicaties 2012
> >
Promotions
12 januari 2012
Jasper H. Smalberg
Promotoren: FWG Leebeek, HLA Janssen
Title: Budd-Chiari syndrome and portal vein thrombosis
9 mei 2012
Marianne C. van Schie
Promotoren: FWG Leebeek
Co-promotor: MPM de Maat
Title: The Influence of Genetic Variation on Van Willebrand Factor Levels and the Risk of Stroke
26 juni 2012
Elim Y.L. Cheung
Promotor: FWG Leebeek
Co-promotor: MPM de Maat
Title: The role of fibrinogen variants in cardiovascular diseases and wound healing
_____________________________________________________________________________________________
Publications
Snijder CA, Cornette JM, Hop WC, Kruip MJ, Duvekot JJ.
Thrombophylaxis and bleeding complications after cesarean section
Acta Obstet Gynecol Scand. 2012;91:560-565
Mulders G, DE Wee EM, Vahedi Nikbakht-VAN DE Sande MC, Kruip MJ, Elfrink EJ, Leebeek FW.
E-learning improves knowledge and practical skills in haemophilia patients on home treatment: a randomized controlled trial
Haemophilia. 2012 Mar 28 EPUB
Biere-Rafi S, Tuinenburg A, Haak BW, Peters M, Huijgen R, De Groot E, Verhamme P, Peerlinck K, Visseren FL, Kruip MJ, Laros-Van Gorkom BA, Gerdes VE, Buller HR, Schutgens RE, Kamphuisen PW.
Factor VIII deficiency does not protect against atherosclerosis
J Thromb Haemost. 2012;10:30-7
Tuinenburg A, Rutten A, Kavousi M, Leebeek FW, Ypma PF, Laros-van Gorkom BA, Nijziel MR, Kamphuisen PW, Mauser-Bunschoten EP, Roosendaal G, Biesma DH, van der Lugt A, Hofman A, Witteman JC, Bots ML, Schutgens RE.
Coronary Artery Calcification in Hemophilia A: No Evidence for a Protective Effect of Factor VIII Deficiency on Atherosclerosis
Arterioscler Thromb Vasc Biol. 2012;32:799-804
Hofstra JJ, Budde IK, van Twuyver E, Choi G, Levi M, Leebeek FW, de Monchy JG, Ypma PF, Keizer RJ, Huitema AD, Strengers PF.
Treatment of hereditary angioedema with nanofiltered C1-esterase inhibitor concentrate (Cetor®): Multi-center phase II and III studies to assess pharmacokinetics, clinical efficacy and safety
Clin Immunol 2012;142:280-290
van Lier F, van der Geest PJ, Hol JW, Leebeek FW, Hoeks SE.
Risk modification for postoperative pulmonary embolism: Timing of postoperative prophylaxis
Thromb Res. 2012;129:14-17
Bouman HJ, van Werkum JW, Rudež G, Hackeng CM, Leebeek FW, Ten Cate H, Ten Berg JM, de Maat MP.
The relevance of P2Y12-receptor gene variation for the outcome of clopidogrel-treated patients undergoing elective coronary stent implantation: A clinical follow-up
Thromb Haemost 2012;107:189-91
Kavousi M, Elias-Smale S, Rutten JH, Leening MJ, Vliegenthart R, Verwoert GC, Krestin GP, Oudkerk M, de Maat MP, Leebeek FW, Mattace-Raso FU, Lindemans J, Hofman A, Steyerberg EW, van der Lugt A, van den Meiracker AH, Witteman JC.
Evaluation of newer risk markers for coronary heart disease risk classification: a cohort study
Ann Intern Med 2012;156:438-44
van der Pas R, de Bruin C, Leebeek FW, de Maat MP, Rijken DC, Pereira AM, Romijn JA, Netea-Maier RT, Hermus AR, Zelissen PM, de Jong FH, van der Lely AJ, de Herder WW, Lamberts SW, Hofland LJ, Feelders RA.
The Hypercoagulable State in Cushing's Disease Is Associated with Increased Levels of Procoagulant Factors and Impaired Fibrinolysis, But Is Not Reversible after Short-Term Biochemical Remission Induced by Medical Therapy
J Clin Endocrinol Metab. 2012 Apr;97(4):1303-10
VAN Schie MC, Wieberdink RG, Koudstaal PJ, Hofman A, Ikram MA, Witteman JC, Breteler MM, Leebeek FW, DE Maat MP.
Genetic determinants of von Willebrand factor plasma levels and the risk of stroke: the Rotterdam Study
J Thromb Haemost. 2012;10:550-556
Brugts JJ, de Maat MP, Danser AH, Boersma E, Simoons ML
Individualised therapy of angiotensin converting enzyme (ACE) inhibitors in stable coronary artery disease: overview of the primary results of the PERindopril GENEtic association (PERGENE) study
Neth Heart J. 2012;20:24-32
Verschuren JJ, Trompet S, Wessels JA, Guchelaar HJ, de Maat MP, Simoons ML, Jukema JW
A systematic review on pharmacogenetics in cardiovascular disease: is it ready for clinical application?
Eur Heart J. 2012;33:165-175
Wils EJ, Aerts-Kaya FS, Rombouts EJ, van Mourik I, Rijken-Schelen A, Visser TP, Braakman E, Wagemaker G, Cornelissen JJ
Keratinocyte Growth Factor and Stem Cell Factor to Improve Thymopoiesis after Autologous CD34(+) Cell Transplantation in Rhesus Macaques.
Biol Blood Marrow Transplant 2012;18:55-65
Visser G, de Jager W, Verhagen LP, Smit GP, Wijburg FA, Prakken BJ, Coffer PJ, Buitenhuis M
Survival, but not maturation, is affected in neutrophil progenitors from GSD-1b patients
J Inherit Metab Dis 2012;35:287-300
Polak R, Buitenhuis M
The PI3K/PKB signaling module as key regulator of hematopoiesis: implications for therapeutic strategies in leukemia.
Blood 2012;119:911-923
Janssen JJ, Deenik W, Smolders KG, van Kuijk BJ, Pouwels W, Kelder A, Cornelissen JJ, Schuurhuis GJ, Ossenkoppele GJ
Residual normal stem cells can be detected in newly diagnosed chronic myeloid leukemia patients by a new flow cytometric approach and predict for optimal response to imatinib
Leukemia 2011 dec; EPUB
Mounier N, Canals C, Gisselbrecht C, Cornelissen J, Foa R, Conde E, Maertens J, Attal M, Rambaldi A, Crawley C, Luan JJ, Brune M, Wittnebel S, Cook G, van Imhoff GW, Pfreundschuh M, Sureda A; for the Lymphoma Working Party of the European Blood and Marrow Transplantation Registry (EBMT).
High-Dose Therapy and Autologous Stem Cell Transplantation in First Relapse for Diffuse Large B Cell Lymphoma in the Rituximab Era: An Analysis Based on Data from the European Blood and Marrow Transplantation Registry
Biol Blood Marrow Transplant. 2011 Oct 17 EPUB
Schmid C, Labopin M, Nagler A, Niederwieser D, Castagna L, Tabrizi R, Stadler M, Kuball J, Corenlissen J, Vorlicek J, Socié G, Falda M, Vindeløv L, Ljungman P, Jackson G, Kröger N, Rank A, Polge E, Rocha V, Mohty M.
Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation
Blood 2012;119:1599-1606
Daenen S, van der Holt B, Dekker AW, Willemze R, Rijneveld AW, Biemond BJ, Muus P, van de Loosdrecht AA, Schouten HC, van Marwijk Kooy M, Breems DA, Demuynck H, Maertens J, Wijermans PW, Wittebol S, de Klerk EW, Cornelissen JJ
Intensive chemotherapy to improve outcome in patients with acute lymphoblastic leukemia over the age of 40. A Phase II Study for Efficacy and Feasibility by HOVON
Leukemia 2012; Feb 23 EPUB
Brunet S, Labopin M, Esteve J, Cornelissen J, Socié G, Iori AP, Verdonck LF, Volin L, Gratwohl A, Sierra J, Mohty M, Rocha V.
Impact of FLT3 Internal Tandem Duplication on the Outcome of Related and Unrelated Hematopoietic Transplantation for Adult Acute Myeloid Leukemia in First Remission: A Retrospective Analysis
J Clin Oncol 2012;30:735-741
Lokhorst HM, van der Holt B, Cornelissen JJ, Kersten MJ, van Oers M, Raymakers R, Minnema MC, Zweegman S, Janssen JJ, Zijlmans M, Bos G, Schaap N, Wittebol S, de Weerdt O, Ammerlaan R, Sonneveld P
Donor versus no donor comparison of newly diagnosed myeloma patients included in the HOVON 50 multiple myeloma study
Blood 2012 Mar 22. EPUB
Nagler A, Labopin M, Shimoni A, Niederwieser D, Mufti GJ, Zander AR, Arnold R, Greinix H, Cornelissen JJ, Jackson GH, Craddock C, Bunjes DW, Ganser A, Russell NH, Kyrcz-Krzemien S, Rocha V, Mohty M.
Mobilized Peripheral Blood Stem Cells Compared with Bone Marrow as the Stem Cell Source for Unrelated Donor Allogeneic Transplantation with Reduced Intensity Conditioning in Patients with Acute Myeloid Leukemia in Complete Remission: An Analysis from the Acute Leukemia Working Party of the European group for Blood and Marrow Transplantation
Biol Blood Marrow Transplant. 2012 Mar 20. EPUB
Chevallier P, Labopin M, Milpied N, Cornelissen JJ, Blaise D, Petersen E, Sandstedt A, Goker H, Socie G, Rocha V, Mohty M.
Impact of cytogenetics risk on outcome after reduced intensity conditioning allo-SCT from an HLA-identical sibling for patients with AML in first CR: a report from the acute leukemia working party of EBMT
Bone Marrow Transplant. 2012 Apr 16. EPUB
Spits H, Cupedo T.
Innate Lymphoid Cells: Emerging Insights in Development, Lineage Relationships, and Function
Annu Rev Immunol. 2012;30:647-675
Alemdehy MF, van Boxtel NG, de Looper HW, van den Berge IJ, Sanders MA, Cupedo T, Touw IP, Erkeland SJ.
Dicer1 deletion in myeloid-committed progenitors causes neutrophil dysplasia and blocks macrophage/dendritic cell development in mice
Blood. 2012 Feb 21. EPUB
Li Z, Huang H, Li Y, Jiang X, Chen P, Arnovitz S, Radmacher MD, Maharry K, Elkahloun A, Yang X, He C, He M, Zhang Z, Dohner K, Neilly MB, Price C, Lussier YA, Zhang Y, Larson RA, Le Beau MM, Caligiuri MA, Bullinger L, Valk PJ,, Delwel R, Lowenberg B, Liu PP, Marcucci G, Bloomfield CD, Rowley JD, Chen J.
Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically-abnormal AML
Blood. 2012;119:2314-2324
Li Z, Huang H, Chen P, He M, Li Y, Arnovitz S, Jiang X, He C, Hyjek E, Zhang J, Zhang Z, Elkahloun A, Cao D, Shen C, Wunderlich M, Wang Y, Neilly MB, Jin J, Wei M, Lu J, Valk PJ, Delwel R. Lowenberg B, Le Beau MM, Vardiman J, Mulloy JC, Zeleznik-Le NJ, Liu PP, Zhang J, Chen J
miR-196b directly targets both HOXA9/MEIS1 oncogenes and FAS tumour suppressor in MLL-rearranged leukaemia
Nat Commun. 2012 Feb 21 EPUB
Zebisch A, Wölfler A, Fried I, Wolf O, Lind K, Bodner C, Haller M, Drasche A, Pirkebner D, Matallanas D, Rath O, Blyth K, Delwel R Taskesen E, Quehenberger F, Kolch W, Troppmair J, Sill H.
Frequent loss of RAF kinase inhibitor protein expression in acute myeloid leukemia
Leukemia. 2012 Mar 5. EPUB
Bergerson RJ, Collier LS, Sarver AL, Been RA, Lugthart S, Diers MD, Zuber J, Rappaport AR, Nixon MJ, Silverstein KA, Fan D, Lamblin AF, Wolff L, Kersey JH, Delwel R, Lowe SW, O'Sullivan MG, Kogan SC, Adams DJ, Largaespada DA.
An insertional mutagenesis screen identifies genes that cooperate with Mll-AF9 in a murine leukemogenesis model
Blood. 2012 Mar 16. EPUB
Ribeiro AF, Pratcorona M, Erpelinck-Verschueren C, Rockova V, Sanders M, Abbas S, Figueroa ME, Zeilemaker A, Melnick A, Löwenberg B, Valk PJ, Delwel R
Mutant DNMT3A: a new marker of poor prognosis in acute myeloid leukemia
Blood. 2012 Apr 5 EPUB
Alemdehy MF, Erkeland SJ.
MicroRNAs: key players of normal and malignant myelopoiesis
Curr Opin Hematol. 2012 Apr 16. EPUB
Pratcorona M, Abbas S, Sanders M, Koenders J, Kavelaars F, Erpelinck-Verschueren C, Löwenberg B, Zeilemaker A, Valk P.
Acquired mutations in ASXL1 in acute myeloid leukemia: prevalence and prognostic value
Haematologica. 2012;97:388-392
Rockova V, Lesaffre E, Luime J, Löwenberg B
Hierarchical Bayesian formulations for selecting variables in regression models
Stat Med. 2012 Jan 25 EPUB
Beekman R, Valkhof MG, Sanders MA, van Strien PM, Haanstra JR, Broeders L, Geertsma-Kleinekoort WM, Veerman AJ, Valk PJ, Verhaak RG, Löwenberg B, Touw IP
Sequential gain of mutations in severe congenital neutropenia progressing to acute myeloid leukemia
Blood. 2012 Feb 27 EPUB
Pabst T, Vellenga E, van Putten W, Schouten HC, Graux C, Vekemans MC, Biemond B, Sonneveld P, Passweg J, Verdonck L, Legdeur MC, Theobald M, Jacky E, Bargetzi M, Maertens J, Ossenkoppele GJ, Löwenberg B.
Favorable effect of priming with granulocyte colony-stimulating factor in remission induction of acute myeloid leukemia restricted to dose-escalation of cytarabine
Blood. 2012 Mar 15 EPUB
Liersch R, Gerss J, Schliemann C, Bayer M, Schwöppe C, Biermann C, Appelmann I, Kessler T, Löwenberg B, Büchner T, Hiddemann W, Müller-Tidow C, Berdel WE, Mesters R.
Osteopontin is a prognostic factor for survival of acute myeloid leukemia patients
Blood. 2012 Apr 17 EPUB
Federzoni EA, Valk PJ, Torbett BE, Haferlach T, Löwenberg B, Fey MF, Tschan MP.
PU.1 is linking the glycolytic enzyme HK3 in neutrophil differentiation and survival of APL cells
Blood. 2012 Apr 12 EPUB
Bromberg JE, Doorduijn JK, Baars JW, van Imhoff GW, Enting R, van den Bent MJ
Acute painful lumbosacral paresthesia after intrathecal rituximab
J Neurol. 2012;259:559-561
Johnsen H, Haioun C, Lugtenburg P, Salar A, Jaeger U, Pettengell R, Rossi F, Verhoef G, Schwenkglenks M, Bendall K, Duehrsen U.
Importance of granulocyte colony-stimulating factor prophylaxis in therapy with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone given every 14 days for diffuse large B-cell lymphoma in routine clinical practice
Leuk Lymphoma 2012;53:982-984
Pettengell R, Johnson HE, Lugtenburg PJ, Silvestre AS, Dührsen U, Rossi FG, Schwenkglenks M, Bendall K, Szabo Z, Jaeger U.
Impact of febrile neutropenia on R-CHOP chemotherapy delivery and hospitalizations among patients with diffuse large B-cell lymphoma
Support Care Cancer 2012;20:647-752
van der Kaaij MA, Heutte N, Meijnders P, Abeilard-Lemoisson E, Spina M, Moser EC, Allgeier A, Meulemans B, Simons AH, Lugtenburg PJ, Aleman BM, Noordijk EM, Fermé C, Thomas J, Stamatoullas A, Fruchart C, Brice P, Gaillard I, Bologna S, Ong F, Eghbali H, Doorduijn JK, Morschhauser F, Sebban C, Roesink JM, Bouteloup M, Van Hoof A, Raemaekers JM, Henry-Amar M, Kluin-Nelemans HC.
Premature Ovarian Failure and Fertility in Long-Term Survivors of Hodgkin's Lymphoma: A European Organisation for Research and Treatment of Cancer Lymphoma Group and Groupe d'Etude des Lymphomes de l'Adulte Cohort Study
J Clin Oncol 2012;30:291-299
van Bijnen ST, van Rijn RS, Koljenovic S, te Boekhorst P, de Witte T, Muus P
Possible high risk of thrombotic events in patients with paroxysmal nocturnal haemoglobinuria after discontinuation of eculizumab
Br J Haematol. 2012 Feb EPUB
Salar A, Haioun C, Rossi FG, Duehrsen U, Pettengell R, Johnsen HE, Jaeger U, Verhoef G, Schwenkglenks M, Bacon P, Bendall K, Lugtenburg PJ
The need for improved neutropenia risk assessment in DLBCL patients receiving R-CHOP-21: Findings from clinical practice
Leuk Res. 2012 May;36:548-53
de Graaff E, Maat P, Hulsenboom E, van den Berg R, van den Bent M, Demmers J, Lugtenburg PJ, Hoogenraad CC, Sillevis Smitt P.
Identification of delta/notch-like epidermal growth factor-related receptor as the Tr antigen in paraneoplastic cerebellar degeneration
Ann Neurol. 2012 Feb 1 EPUB
Bellido M, Te Boekhorst PA.
JAK2 Inhibition: Reviewing a New Therapeutical Option in Myeloproliferative Neoplasms
Adv Hematol 2012 Feb 16 EPUB
Raaijmakers MH
Myelodysplastic syndromes: revisiting the role of the bone marrow microenvironment in disease pathogenesis
Int J Hematol 2012;95:17-25
Kumar SK, Lee JH, Lahuerta JJ, Morgan G, Richardson PG, Crowley J, Haessler J, Feather J, Hoering A, Moreau P, Leleu X, Hulin C, Klein SK, Sonneveld P, Siegel D, Bladé J, Goldschmidt H, Jagannath S, Miguel JS, Orlowski R, Palumbo A, Sezer O, Rajkumar SV, Durie BG; on behalf of the International Myeloma Working Group; International Myeloma Working Group, Abildgaard N, Abonour R, Alexanian R, Alsina M, Anderson KC, Attal M, Avet-Loiseau H, Badros A, Baris D, Barlogie B, Bataille R, Beksaç M, Belch A, Ben-Yehuda D, Bensinger B, Leif Bergsagel P, Bird J, Bladé J, Boccadoro M, Cavo M, Chanan-Khan A, Ming Chen W, Child T, Chim J, Chng WJ, Comenzo R, Crowley J, Dalton W, Davies F, de Souza C, Delforge M, Dimopoulos M, Dispenzieri A, Drach J, Drake M, Durie BG, Einsele H, Facon T, Fantl D, Fermand JP, Fonseca R, Gahrton G, García-Sanz R, Gasparetto C, Gertz M, Gibson J, Giralt S, Goldschmidt H, Greipp P, Hajek R, Hardan I, Hari P, Harousseau JL, Hata H, Hattori Y, Heffner T, Ho J, Hungria V, Ida S, Jacobs P, Jagannath S, Johnsen H, Jian H, Joshua D, Jurczyszyn A, Kawano M, Kröger N, Kumar S, Kyle RA, Lacy M, Lahuerta JJ, Landgren O, Laubach J, Lee JH, Leleu X, Lentzsch S, Lokhorst H, Lonial S, Ludwig H, Maiolino A, Mateos M, Mehta J, Mellqvist UH, Merlini G, Mikhael J, Morales AR, Moreau P, Morgan G, Nari H, Munshi N, Niesvizky R, Nouel A, Novis Y, Orlowski R, Palumbo A, Pavlovsky S, Pilarski L, Powles R, Raje N, Vincent Rajkumar S, Reece D, Reiman T, Richardson PG, Roodman D, Rosiñol L, Miguel JS, Sezer O, Shah JJ, Shaughnessy J, Shimizu K, Shustik C, Siegel D, Singhal S, Sonneveld P, Spencer A, Stadtmauer E, Stewart K, Terpos E, Tosi P, Tricot G, Turesson I, Van Camp B, Van Ness B, Van Riet I, Broek IV, Vanderkerken K, Vescio R, Vesole D, Waage A, Wang M, Weber D, Westin J, Wheatley K, Zonder J.
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
Leukemia 2012;26:149-157
Neben K, Lokhorst HM, Jauch A, Bertsch U, Hielscher T, van der Holt B, Salwender H, Blau IW, Weisel K, Pfreundschuh M, Scheid C, Dührsen U, Lindemann W, Schmidt-Wolf IG, Peter N, Teschendorf C, Martin H, Haenel M, Derigs HG, Raab MS, Ho AD, van de Velde H, Hose D, Sonneveld P, Goldschmidt H.
Administration of bortezomib before and after autologous stem-cell transplantation improves outcome in multiple myeloma patients with deletion 17p
Blood 2012;119:940-948
Palumbo A, Bladé J, Boccadoro M, Palladino C, Davies F, Dimopoulos M, Dmoszynska A, Einsele H, Moreau P, Sezer O, Spencer A, Sonneveld P, San Miguel J.
How to Manage Neutropenia in Multiple Myeloma
Clin Lymphoma Myeloma Leuk 2012;12:5-11
Richardson PG, Delforge M, Beksac M, Wen P, Jongen JL, Sezer O, Terpos E, Munshi N, Palumbo A, Rajkumar SV, Harousseau JL, Moreau P, Avet-Loiseau H, Lee JH, Cavo M, Merlini G, Voorhees P, Chng WJ, Mazumder A, Usmani S, Einsele H, Comenzo R, Orlowski R, Vesole D, Lahuerta JJ, Niesvizky R, Siegel D, Mateos MV, Dimopoulos M, Lonial S, Jagannath S, Bladé J, Miguel JS, Morgan G, Anderson KC, Durie BG, Sonneveld P
Management of treatment-emergent peripheral neuropathy in multiple myeloma
Leukemia 2012;26:595-608
Morgan G, Johnsen HE, Goldschmidt H, Palumbo A, Cavo M, Sonneveld P, Miguel JS, Chim CS, Browne P, Einsele H, Waage A, Turesson I, Spencer A, Hajek R, Ludwig H, Hemminki K, Houlston R
MyelomA Genetics International Consortium
Leuk Lymphoma 2012;53:796-800
Ludwig H, Durie BG, McCarthy P, Palumbo A, San Miguel J, Barlogie B, Morgan G, Sonneveld P, Spencer A, Andersen KC, Facon T, Stewart KA, Einsele H, Mateos MV, Wijermans P, Waage A, Beksac M, Richardson PG, Hulin C, Niesvizky R, Lokhorst H, Landgren O, Bergsagel PL, Orlowski R, Hinke A, Cavo M, Attal M
IMWG consensus on maintenance therapy in multiple myeloma
Blood. 2012;13:3003-3015
Ross F, Avet-Loiseau H, Ameye G, Gutierrez NC, Liebisch P, O' Connor S, Dalva K, Fabris S, Testi AM, Jarosova M, Collin A, Kerndrup G, Kuglik P, Ladon D, Bernasconi P, Maes B, Zemanova Z, Michalova K, Michaux L, Neben K, Hermansen NE, Rack K, Rocci A, Protheroe R, Chiecchio L, Poirel HA, Sonneveld P, Nyegaard M, Johnsen HE
Report from the european myeloma network on interphase FISHin multiple myeloma and related disorders
Haematologica. 2012 Feb 27 EPUB
Horos R, Ijspeert H, Pospisilova D, Sendtner R, Andrieu-Soler C, Taskesen E, Nieradka A, Cmejla R, Sendtner M, Touw IP, von Lindern M.
Ribosomal deficiencies in Diamond-Blackfan anemia impair translation of transcripts essential for differentiation of murine and human erythroblasts
Blood 2012;119:262-272
de Bruin AM, Libregts SF, Valkhof M, Boon L, Touw IP, Nolte MA.
IFNy induces monopoiesis and inhibits neutrophil development during inflammation
Blood 2012;119:1543-1554
Pevsner-Fischer M, Levin S, Hammer-Topaz T, Cohen Y, Mor F, Wagemaker G, Nagler A, Cohen IR, Zipori D
Stable Changes in Mesenchymal Stromal Cells from Multiple Myeloma Patients Revealed through Their Responses to Toll-Like Receptor Ligands and Epidermal Growth Factor
Stem Cell Rev 2012 EPUB